CALL FOR ABSTRACTS

ABSTRACT SUBMISSION SITE OPEN: NOVEMBER 1, 2016 – JANUARY 30, 2017

ASGCT 20th Annual Meeting
Washington, DC • May 10-13, 2017
CALL FOR ABSTRACTS

ASGCT

Through its educational programs and services, ASGCT strives to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapeutics to alleviate human disease.

MEETING INFORMATION

ASGCT's Annual Meeting is the primary forum for the Society to serve as a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

The ASGCT 20th Annual Meeting will take place May 10 – 13, 2017 at the Marriott Wardman Park Hotel in Washington, DC, USA.

The target audience includes basic science and translational researchers, clinical investigators, physicians, postdoctoral fellows, graduate students, other healthcare professionals and employees of federal government and regulatory agencies, academic institutions and the biotechnology industry with an interest in the latest advancements in the field of gene and cell therapies.

INDUSTRY MATCHMAKING SESSIONS

ASGCT is again offering the opportunity for abstract presenters and company representatives at the 20th Annual Meeting to meet one-on-one in private meeting rooms. Abstract presenters will be given 20-30 minutes to present their work and facilitate discussion. The Industry Matchmaking Program provides abstract presenters with a great opportunity to discuss potential new collaborative research agreements, present interesting new technologies, and to identify potential employment opportunities in leading gene and cell therapy companies.

Abstract presenters interested in participating in the Industry Matchmaking Sessions must sign up during the abstract submission process. Due to space constraints, the Industry Matchmaking Program will be open to a limited number of abstract presenters on a first-come first-serve basis.

AVAILABLE FUNDING SUPPORT AND AWARDS

- **Free Annual Meeting registration** will be given to students and postdoctoral fellows who are Associate Members and the first and presenting author of the abstract (either oral or poster).
- ASGCT will be offering **Meritorious Abstract Travel Awards** to postdoctoral fellows and students who are Associate Members of ASGCT by January 30, 2017. These awards ($600 International; $500 Domestic) will be given to those Associate Members who receive an average abstract review score of between 1 and 3.5.
- ASGCT will be giving **Outstanding Poster Presentation Awards** during each poster session to presenters who have been judged to have the best poster presentation in their category, by the respective category’s Poster Presentation Review Team.
- Up to 30 Associate Members will also receive funding ($129 value) for their poster production. ASGCT will pay the cost for the poster production directly to the poster printing service.
- ASGCT will be offering 5 **Underrepresented Minority Travel Awards** for students and postdoctoral fellows submitting abstracts for the meeting. The top 5 candidates for this award, based on average score, will receive a $500 travel award to the 20th Annual Meeting. Candidates who are also eligible to receive a Meritorious Abstract Travel Award based on their score, will receive that award, and not receive the Underrepresented Minority Travel Award. The criteria to be considered for this award are:
  - Candidate must be a U.S. resident and self-identify as belonging to one of the following groups:
    - African American
    - Pacific Islander
    - Hispanic
    - Native American, Inuit, or Aleut
  - Candidate must be an Associate Member of ASGCT.
  - Candidate must be the first and presenting author of an abstract being submitted for the 20th Annual Meeting.

Meritorious Abstract Travel Awards, Underrepresented Minority Travel Awards and poster funding will be awarded based on abstract review scores and a determination of the ASGCT Abstract Review Committees. Please Note: Meeting registration fees are non-reimbursable; travel grant recipients must register for the meeting and will receive a **free registration** if they are an Associate Member and the first and presenting author of the abstract.
CALL FOR ABSTRACTS

ABSTRACT SUBMISSION INFORMATION

The abstract submission site will go live at www.asgct.org/am17 on November 1, 2016.

Abstract submission deadline: January 30, 2017 at 6:00 PM EST.

- Approximately 25% of the abstracts submitted by the above deadline will be eligible for oral presentations based on the review scores and the determination of the Abstract Review Committees. The Committees will also determine where abstracts will be placed within the program.
- ASGCT strongly encourages the presentation of abstracts by postdoctoral fellows and students whenever possible. The presentation of abstracts (oral or poster) is the perfect opportunity for postdoctoral fellows and students to present their research to an audience of researchers at a major international scientific meeting, gaining experience presenting to an audience of their peers. Postdoctoral fellows and students who join ASGCT as Associate Members and submit an accepted abstract as a first and presenting author will receive free registration to the conference!
- All accepted abstracts will be published in the May Supplement to Molecular Therapy.
- Please Note: There will be no printed abstract supplement distributed at the Annual Meeting. The supplement will be published online and available for download in April 2017 on the Molecular Therapy site. The abstracts will also be available through the ASGCT Mobile App, and on the ASGCT website (www.asgct.org) through a link beginning in April 2017.
- There is no fee to submit an abstract.

To begin the submission process, please go directly to www.asgct.org/am17.

ELIGIBILITY

- ASGCT Members and non-Members are eligible to submit an abstract.
- Submitting an abstract does not register you for the meeting. You must register for the meeting to present your abstract. Meeting registration will be available online at www.asgct.org/am17 in December 2016.

Please do not submit an abstract if you are not prepared to travel to the meeting and present it in the form selected by ASGCT.

INELIGIBILITY

- Papers that have been accepted for publication or published prior to the abstract submission deadline may not be submitted unless special consideration is requested.

If your abstract was previously accepted for presentation at ASGCT or another nation/international meeting, do not submit the abstract unless special permission is requested and granted from ASGCT.

INTERNATIONAL ABSTRACT SUBMITTERS

International abstract submitters who plan to attend the ASGCT 20th Annual Meeting will need to apply for a VISA to travel to the meeting in Washington, DC, USA.

Please Note: The amount of time required to obtain a VISA has increased tremendously. For the 2017 Annual Meeting, ASGCT will send invitation letters to all abstract submitters so they can apply for their VISA, immediately upon receiving their abstract submission.

Contact the ASGCT office immediately for an official letter from ASGCT as part of your VISA application, if you have not already received one. Please send your request to Emily Hutmacher (ehutmacher@asgct.org) at ASGCT.

ABSTRACT TOPIC CATEGORIES

When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract.

Please note that abstract categories have been modified to reflect continued developments in the field and to clarify submissions for the 2017 Annual Meeting.

A. Viral Vector Development (includes regulation of gene expression)
- Vectors not specifically mentioned should be directed to the most closely related category. Hybrid vectors should be directed to the category that makes the largest contribution to the performance of the vector system.
  - A1. RNA Virus Vectors
  - A2. AAV Vectors
  - A3. Adenovirus Vectors and Other DNA Viruses

B. Gene Targeting and Gene Correction (includes genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.)
  - C. Oligonucleotide Therapeutics (siRNAs, aptamers, antagonirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
  - D. Synthetic/Molecular Conjugates and Non-Viral Methods for Delivery of Gene Therapeutics (including exosomes)
  - E. Disease Models and Clinical Applications (includes inherited and acquired diseases, animal models, and clinical trials)
    - E1. Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
    - E2. Cardiovascular and Pulmonary Diseases
    - E3. Neurologic Diseases (including Ophthalmic and Auditory Diseases)
    - E4. Musculo-Skeletal Diseases
    - E5. Cancer – Immunotherapy, Cancer Vaccines
    - E6. Cancer – Oncolytic Viruses
    - E7. Cancer – Targeted Gene and Cell Therapy
    - E8. Hematologic and Immunologic Diseases

(May 2017)
CALL FOR ABSTRACTS

ABSTRACT TOPIC CATEGORIES (CONTINUED)

F. Immunological Aspects of Gene Therapy and Vaccines (includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)

G. Cell Therapies (includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)

H. Clinical Translation of Gene and Cell Therapies
   H1. Vector and Cell Engineering, Production or Manufacturing
   H2. Pharmacology/Toxicology Studies or Assay Development
   H3. Clinical Protocol Development, Regulatory Interactions, and Ethics

NOTIFICATION OF ABSTRACT ACCEPTANCE AND AWARDS

Notification regarding acceptance or non-acceptance of abstracts will be delivered in mid-late March 2017 via email, with official letters available online for download. Meritorious Abstract Travel Awards, Excellence in Research Award, and Underrepresented Minority Travel Award acceptance and non-acceptance letters will also be sent at this time.

ACCEPTANCE OF PRESENTATION

All notified abstract presenters are required to accept their presentation as instructed in their notification email. This can be done online through the abstract submission site.

LATE BREAKING ABSTRACT SUBMISSIONS

ASGCT will not be accepting Late Breaking Abstract submissions for the 20th Annual Meeting.

ABSTRACT QUESTIONS

For all questions regarding the abstract submission process, please contact Coe-Truman Technologies’ Technical Support by phone at 1-217-398-1792 or by email at oasis@support.cltmeetingtech.com. If you would like to make changes to your abstract after submitting it, you will now be able to return directly to your abstract and make changes until the deadline.

Technical Support is open Monday – Friday during the following hours:
9:00 am – 6:00 pm EST
8:00 am – 5:00 pm CST
7:00 am – 4:00 pm MST
6:00 am – 3:00 pm PST